ABBV vs. AVGO: AbbVie vs. Broadcom Stock Comparison

Company Profile

AbbVie (ABBV) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Broadcom (AVGO) belongs to Information Technology (Semiconductors & Semiconductor Equipment) — their GICS classifications point to very different parts of the market.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Broadcom (AVGO) has an aggressive beta of 1.50, indicating higher sensitivity to broad-market moves, while AbbVie (ABBV) is defensive at 0.21 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Broadcom (AVGO) earns 44.25% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

For every dollar of sales, both AbbVie (ABBV) at 15.67% and Broadcom (AVGO) at 42.94% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both AbbVie (ABBV) at 39.59% and Broadcom (AVGO) at 54.31% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both AbbVie (ABBV) at 8.57% and Broadcom (AVGO) at 23.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Broadcom (AVGO) at 287.80% clears its industry range for EPS growth, a much stronger earnings trajectory than AbbVie (ABBV) at -0.84%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Broadcom (AVGO) at 2.50 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.

Only one side’s leverage can be read here: Broadcom (AVGO) carries debt-to-equity ratio of 0.60 against its industry range, while AbbVie (ABBV) reports no figure this period.

Financial Strength Metrics

Dividends

Broadcom (AVGO) at 0.89% earns its spot in the top quartile of its industry’s yields; AbbVie (ABBV) at 2.40% is past the top of its own peer range — territory where a dividend-safety check matters more than the headline number.

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Broadcom (AVGO) reports 32.44%, ranking against industry peers normally.

Dividend Metrics

Valuation

Broadcom (AVGO) at 37.51 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 50.05 sits in the richer quartile — ABBV needs stronger growth or earnings quality to justify the premium.

AbbVie (ABBV) at 7.80 is priced about in line with its industry on P/S ratio, while Broadcom (AVGO) at 15.73 sits in the pricier quartile — AVGO costs more per dollar of sales.

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Broadcom (AVGO) reports 14.06, ranking against industry peers normally.

Valuation Metrics